BTIG analyst Justin Zelin downgraded TScan Therapeutics (TCRX) to Neutral from Buy without a price target following the company’s decision to prioritize its hematologic malignancy program and pause on enrollment in the solid tumor TCR-T study. BTIG now assumes a late-2029 approval for TSC-101. It cites the delay in an expected TSC-101 launch and removal of the solid-tumor program, coupled with limited near-term share catalysts, for the downgrade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCRX:
- TScan Therapeutics downgraded to Neutral from Buy at BTIG
- TScan Therapeutics price target lowered to $6 from $9 at Needham
- TScan Therapeutics’ TSC-101 Gains Buy Rating Amid Promising Trial Results and Strategic Focus on Heme Program
- TScan Therapeutics Shifts Focus to Hematologic Malignancies
- TScan Therapeutics to reduce workforce by 30%